The research team, led by Henan Wang and Xindi Liu with corresponding authors Liang Wang and Jia Cong, followed 96 consecutive patients treated between November 2022 and March 2025. All had relapsed or refractory B-cell malignancies, the population in which CAR-T products have shown their greatest success. The median age was 56.5 years, with an interquartile range of 46 to 66.5, reflecting the typical demographic of lymphoma patients referred for cellular therapy. Rather than relying on the older Common Terminology Criteria for Adverse Events alone, the investigators graded blood toxicity using the recently formalized immune effector cell-associated hematotoxicity framework, known as ICAHT, which distinguishes neutropenia, or N-ICAHT, from thrombocytopenia, or T-ICAHT, and tracks each on its own timeline.

That distinction matters clinically. Neutropenia strips patients of their main defense against bacterial and fungal infections, while thrombocytopenia raises the risk of spontaneous bleeding, including intracranial hemorrhage in the most severe cases. The two complications have different kinetics, different risk factors, and different management strategies, yet many earlier studies lumped them together under a single hematologic toxicity label. By separating them, the Beijing team could ask whether the predictors of a crashing neutrophil count differ from the predictors of a crashing platelet count, and the answer turned out to be yes, at least in degree.

The efficacy backdrop of the cohort was consistent with published experience. The overall response rate reached 78.3 percent at one month after infusion and settled to 65.5 percent at three months. Classical acute toxicities were common but rarely severe: cytokine release syndrome occurred in 74.0 percent of patients, yet only 2.1 percent experienced grade 3 or higher episodes, and immune effector cell-associated neurotoxicity syndrome appeared in 10.4 percent of patients, of which 5.2 percent were grade 3 or higher. These figures confirm that in experienced centers the inflammatory toxicities that dominated early CAR-T literature are now largely manageable, leaving hematologic recovery as the dominant safety concern.

The neutrophil data tell a stark story. Grade 3 to 4 neutropenia peaked at day 4 after infusion, when 71.9 percent of patients had severely depleted counts, and although most recovered, 34.7 percent still had severe neutropenia at day 28. Persistent suppression a month after infusion is the point at which infectious risk compounds, since patients remain on prophylactic antivirals and often prophylactic antibiotics, and any breakthrough infection can escalate rapidly. To predict who would fare worst, the team stratified patients using the CAR-HEMATOTOX score, a pre-infusion composite that incorporates baseline blood counts, inflammatory markers such as ferritin and C-reactive protein, and disease burden. The score was calculable in 86 patients, and 31 of them, or 36.0 percent, fell into the high-risk category of 2 or above.

The stratification worked. Severe early N-ICAHT, defined as grade 3 to 4 neutropenia in the early window after infusion, occurred in 16.1 percent of high-risk patients compared with 3.6 percent of low-risk patients, a statistically significant difference with a p value of 0.013. In multivariable logistic regression, where candidate predictors were first filtered through LASSO regression to avoid overfitting, a CAR-HEMATOTOX score of 2 or higher was the only significant predictor of severe early neutropenia, with an adjusted odds ratio of 4.04 and a 95 percent confidence interval of 1.01 to 22.17. For late neutropenia, a different factor emerged: patients who had received bridging therapy, meaning anti-cancer treatment given between lymphodepletion planning and CAR-T infusion, had an adjusted odds ratio of 4.25, with a confidence interval of 1.64 to 10.98, for developing late-phase neutropenia.

Thrombocytopenia told an even sharper story. High-risk patients by CAR-HEMATOTOX developed severe early T-ICAHT at a rate of 74.2 percent versus 25.5 percent in low-risk patients, and late T-ICAHT at 80.6 percent versus 47.3 percent, both differences highly significant with p values below 0.001. The CAR-HEMATOTOX score was the strongest adjusted predictor of both early and late thrombocytopenia, with adjusted odds ratios of 8.22 and 4.20 respectively. The authors suggest this stronger association for platelets may reflect the score’s inclusion of baseline platelet count and inflammatory burden, both of which directly bear on platelet production and consumption. Perhaps the most provocative observation was that 9 of the 10 patients who developed neurotoxicity, 90 percent, also developed thrombocytopenia. The team frames this as hypothesis-generating, noting it may point to shared endothelial injury pathways linking brain vascular leakage and platelet decline, while cautioning that residual confounding cannot be excluded in an observational design.

The study also addressed a long-running practical debate: whether the supportive care used to rescue blood counts might itself fan the inflammatory toxicities of CAR-T. Growth factor support with granulocyte colony-stimulating factor, G-CSF, was given to 78.1 percent of patients, and thrombopoietin receptor agonists, TPO-RA, to 48.9 percent. Neither intervention was associated with an increased rate of grade 3 or higher cytokine release syndrome or neurotoxicity. This is reassuring for clinicians who worry that stimulating recovering myeloid cells could amplify the cytokine storm, and it supports the increasingly common practice of early, aggressive count support in the weeks after infusion. The authors are careful to note that within the limits of the observational design, this finding cannot establish causality in either direction, but it removes a major practical objection to using these drugs.

What the study cannot do, by its own design, is settle questions of causation or generalize beyond a single center. As a retrospective cohort at one Chinese hospital, it captures real-world practice, including the bridging therapies and supportive care patterns actually used, but it lacks the randomization needed to prove that the CAR-HEMATOTOX score modifies risk rather than merely marking it. The confidence interval around the early neutropenia odds ratio, stretching from barely above 1 to more than 22, reflects the modest sample size of 96 patients. Still, the consistency of the signal across both neutropenia and thrombocytopenia, and its alignment with prior validation work on the score in European and American cohorts, strengthens the case that pre-infusion risk stratification should become routine.

The practical implications are immediate. Patients flagged as high risk before infusion could be considered for closer platelet monitoring, earlier thrombopoietin receptor agonist initiation, lower thresholds for transfusion, and heightened vigilance for neurologic symptoms given the observed overlap with ICANS. The finding that bridging therapy predicts late neutropenia adds weight to the argument for minimizing or carefully selecting pre-infusion treatment in patients who can safely proceed directly to CAR-T. As CAR-T therapy expands beyond academic centers into community oncology, tools like the CAR-HEMATOTOX score offer a way to bring sophisticated risk assessment to settings without specialized cellular therapy infrastructure. The Beijing cohort suggests that the era of treating CAR-T hematotoxicity as an unpredictable hazard is ending, replaced by a framework in which the patients most likely to crash are identifiable before the first engineered cell is infused.

Subject of Research: Hematologic toxicity, including neutropenia and thrombocytopenia, following CAR-T cell therapy for B-cell malignancies

Article Title: Analysis of hematologic toxicity profiles following CAR-T cell therapy: a retrospective cohort study

Article References: Wang, H., Liu, X., Li, F., Liang, Y., Zeng, L., Zhu, J., Wang, L., & Cong, J. (2026). Analysis of hematologic toxicity profiles following CAR-T cell therapy: a retrospective cohort study. BMC Cancer. https://doi.org/10.1186/s12885-026-16932-0

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16932-0

Keywords: CAR-T cell therapy, ICAHT, neutropenia, thrombocytopenia, CAR-HEMATOTOX, hematologic toxicity, B-cell malignancy, cytokine release syndrome, ICANS, G-CSF, thrombopoietin receptor agonist, retrospective cohort study

CD19 has become the single most important target in B-cell malignancy therapy. Chimeric antigen receptor T-cell therapies, bispecific antibodies, and antibody-drug conjugates overwhelmingly depend on the dense, consistent expression of CD19 on the surface of malignant B lymphocytes. Yet relapse after CD19-directed immunotherapy is common, and one of the best-documented mechanisms of that relapse is the loss or masking of surface CD19. Tumor cells that downregulate the antigen effectively become invisible to the therapy, resuming their growth once the immune pressure has been evaded. Understanding what controls CD19 abundance at the cell surface, and how clinical drugs might stabilize it, is therefore a question of substantial therapeutic consequence. The new work addresses that question directly, and its answer involves an unlikely player.

Matriptase, encoded by the ST14 gene, is a type II transmembrane serine protease with a well-established role in epithelial biology. It is best known for initiating proteolytic cascades that regulate barrier function, filaggrin processing, and growth factor signaling in skin and other epithelial tissues. Its dysregulation has been implicated in epithelial cancers, where excessive matriptase activity can promote invasion and metastasis. Its role in lymphoid malignancies, by contrast, has been far less explored. The new study now places matriptase at the center of a drug-responsive circuit in malignant B cells, where it appears to act on the fate of CD19 itself, preserving the antigen in its extracellular, antibody-accessible form rather than allowing it to be shed, internalized, or otherwise lost from the cell surface.

The central observation is a causal chain. When malignant B cells are exposed to ibrutinib, the drug does more than inhibit BTK signaling; it triggers an increase in matriptase activity or abundance. That protease, in turn, acts to maintain extracellular CD19. In practical terms, cells treated with the drug retain the surface target that CAR-T cells and CD19-directed antibodies recognize, whereas cells in which the matriptase arm of this circuit is disrupted lose that protection and become prone to antigen escape. The authors frame this as a mechanism by which ibrutinib limits antigen escape in B-cell malignancy, a framing that carries immediate translational weight because ibrutinib is already approved and widely used in chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell disorders.

The clinical logic of the finding is compelling. Ibrutinib and CD19-directed immunotherapies are frequently considered in overlapping patient populations, and sequencing decisions between BTK inhibition and cellular immunotherapy are often made empirically. If ibrutinib treatment stabilizes surface CD19, then a period of BTK inhibition before leukapheresis or CAR-T infusion could, in principle, improve the quality of the target presented to the engineered cells, reducing the likelihood that the manufactured product encounters antigen-low tumor cells. Conversely, the study raises a caution: interventions or tumor adaptations that suppress matriptase might undermine CD19 display and thereby predispose patients to escape from CD19-directed therapies, even when the malignant cells remain otherwise sensitive to cytotoxic pressure.

Antigen escape is not a single mechanism but a family of them. Tumor cells can mutate the CD19 locus, introduce truncating mutations, alter exon splicing so that the epitope is lost while the protein remains, internalize the antigen faster than it is replaced, or shield it from antibody binding through changes in the membrane microenvironment. Each of these routes has been documented in patients relapsing after CD19 CAR-T therapy. What the new study contributes is the idea that the extracellular maintenance of CD19 is an actively regulated process, one that a protease can influence and that an approved drug can modulate. That reframing matters because it converts antigen loss from an apparently random escape event into a process with identifiable molecular control points that might be monitored and manipulated.

The mechanistic details also connect two previously separate strands of B-cell biology. BTK signaling sits at the heart of the B-cell receptor pathway, and its chronic engagement is a hallmark of many B-cell malignancies, particularly those dependent on active B-cell receptor signaling such as chronic lymphocytic leukemia and mantle cell lymphoma. Ibrutinib’s inhibition of BTK disrupts survival signals and drives malignant cells toward apoptosis. The new data suggest that this well-characterized pharmacologic action has a second, previously underappreciated consequence: a protease-mediated remodeling of the tumor cell surface that favors target retention. In effect, a drug designed to weaken the tumor may simultaneously make the tumor easier to see for the immune system, an unintended benefit that could be exploited deliberately.

For researchers in the immunotherapy field, the study suggests several lines of immediate follow-up. Measuring matriptase activity in patient samples before CD19-directed therapy could reveal whether protease status predicts who is at risk of antigen-negative relapse. Pharmacologic or genetic modulation of matriptase in preclinical models could test whether enhancing its activity further improves CD19 persistence under immune pressure. Combination trials pairing ibrutinib with CD19 CAR-T or bispecific antibodies are already underway for various indications, and the new mechanism provides a biological rationale for such combinations that goes beyond simple additive cytotoxicity. Biomarker strategies that track surface CD19 density longitudinally during BTK inhibition could also help clinicians time cellular therapy infusions for maximal target availability.

There are, of course, important caveats. Matriptase is a protease with pleiotropic effects, and its activity in epithelial cancers has often been associated with tumor progression, so any therapeutic strategy aimed at boosting its function in lymphoid malignancy would need to account for tissue-specific context and potential off-tumor consequences. The relationship between ibrutinib exposure, matriptase activation, and CD19 maintenance will also need to be validated across the full diversity of B-cell malignancies, since the biology of chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and mantle cell lymphoma differ substantially in their dependence on BTK signaling and their patterns of antigen expression. Clinical outcomes, not only cell-culture measurements, will ultimately determine whether the mechanism translates into lower rates of antigen-escape relapse in treated patients.

Even with those qualifications, the study adds a genuinely new concept to the immunotherapy conversation: that the target itself can be pharmacologically defended. Much of the effort in overcoming antigen escape has focused on the therapeutic side, through multi-antigen CAR constructs targeting CD19 together with CD20 or CD22, or through sequential and dual-targeting strategies. The alternative approach suggested here is to act on the tumor cell so that it continues to display the antigen the therapy needs. If ibrutinib-triggered matriptase activity proves to be a reliable and safe lever for maintaining extracellular CD19, it would represent a rare example of an approved small-molecule drug being repurposed, at least conceptually, as a target-preservation agent for cellular immunotherapy. In a field where antigen loss remains one of the leading causes of treatment failure, that is an idea with the potential to reshape how BTK inhibitors and CD19-directed therapies are sequenced and combined in the clinic.

Subject of Research: Ibrutinib-triggered matriptase activity maintains extracellular CD19 and limits antigen escape in B-cell malignancy

Article Title: Ibrutinib-triggered matriptase maintains extracellular CD19 and limits antigen escape in B-cell malignancy

Article References: Lu, X.-J., Lai, H.-F., Hung, Y.-S., Wang, Y.-J., Wu, S.-C., Wang, J.-K., Wu, Y.-Y., & Chiu, Y.-L. (2026). Ibrutinib-triggered matriptase maintains extracellular CD19 and limits antigen escape in B-cell malignancy. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03306-5

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03306-5

Keywords: ibrutinib, matriptase, CD19, antigen escape, B-cell malignancy, BTK inhibitor, CAR-T therapy, immunotherapy, Cell Death Discovery, serine protease, chronic lymphocytic leukemia, target preservation